US 12,419,866 B2
Compounds and methods for treating an epileptic disorder
Scott C. Baraban, Novato, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jun. 26, 2023, as Appl. No. 18/341,626.
Application 18/341,626 is a division of application No. 15/892,204, filed on Feb. 8, 2018, granted, now 11,684,609.
Application 15/892,204 is a continuation of application No. 15/047,254, filed on Feb. 18, 2016, granted, now 9,925,172, issued on Mar. 27, 2018.
Application 15/047,254 is a continuation of application No. PCT/US2014/051731, filed on Aug. 19, 2014.
Claims priority of provisional application 61/867,397, filed on Aug. 19, 2013.
Prior Publication US 2023/0372304 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4184 (2006.01); A61K 31/137 (2006.01); A61K 31/19 (2006.01); A61K 31/195 (2006.01); A61K 31/197 (2006.01); A61K 31/20 (2006.01); A61K 31/27 (2006.01); A61K 31/357 (2006.01); A61K 31/36 (2006.01); A61K 31/4015 (2006.01); A61K 31/4166 (2006.01); A61K 31/433 (2006.01); A61K 31/473 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61K 31/7048 (2006.01); A61K 33/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/20 (2013.01); A61K 31/27 (2013.01); A61K 31/357 (2013.01); A61K 31/36 (2013.01); A61K 31/4015 (2013.01); A61K 31/4166 (2013.01); A61K 31/433 (2013.01); A61K 31/473 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/7048 (2013.01); A61K 33/00 (2013.01); A61K 45/06 (2013.01)] 17 Claims
 
1. A method of treating an epilepsy disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of one or more of clemizole, a pharmaceutically acceptable salt of clemizole, a clemizole analog, or a pharmaceutically acceptable salt of the clemizole analog and an anti-epilepsy drug (AED);
wherein:
the clemizole is not combined with another active compound capable of treating said epilepsy disorder;
the anti-epilepsy drug is selected from the group consisting of acetazolamide, benzodiazepine, cannabadiols, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, ethotoin, felbamate, fenfluramine, fosphenytoin, gabapentin, ganaxolone, huperzine A, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, potassium bromide, pregabalin, primidone, retigabine, rufinamide, sodium valproate, stiripentol, tiagabine, vigabatrin, and zonisamide;
the clemizole analog having the structure of formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is

OG Complex Work Unit Chemistry
wherein the aryl is a substituted or unsubstituted aryl selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
R2 is selected from hydrogen, CH3, —CF3, —CH2CH3, CH3OH,

OG Complex Work Unit Chemistry
wherein X is selected from the group consisting of

OG Complex Work Unit Chemistry
wherein in the

OG Complex Work Unit Chemistry
group the alkyl is an unsubstituted alkyl;
each of R4-R7 is independently selected from the group consisting of

OG Complex Work Unit Chemistry
or one or two sets selected from R4 and R5, R5 and R6, or R6 and R7 connected by a 5-6 membered ring having a structure

OG Complex Work Unit Chemistry
and the members of R4-R7 not connected by the 5-6-member ring are selected from the above-listed alternatives for R4-R7; and
n is an integer from 1 to 2.